Print Page

Other safety alerts

 
The United States: FDA Drug Safety Communication: Codeine use in certain children after tonsillectomy and/or adenoidectomy may lead to rare, but life-threatening adverse events or death
 
The U.S. Food and Drug Administration (FDA) is reviewing reports of children who developed serious adverse effects or died after taking codeine for pain relief after tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome.
Recently, three pediatric deaths and one non-fatal but life-threatening case of respiratory depression were documented in the medical literature. These children (ages two to five) had evidence of an inherited (genetic) ability to convert codeine into life-threatening or fatal amounts of morphine in the body. All children had received doses of codeine that were within the typical dose range.
When codeine is ingested, it is converted to morphine in the liver by an enzyme called cytochrome P450 2D6 (CYP2D6). Some people have DNA variations that make this enzyme more active, causing codeine to be converted to morphine faster and more completely than in other people. These “ultra-rapid metabolizers” are more likely to have higher than normal amounts of morphine in their blood after taking codeine. High levels of morphine can result in breathing difficulty, which may be fatal. Taking codeine after tonsillectomy and/or adenoidectomy may increase the risk for breathing problems and death in children who are “ultra-rapid metabolizers”.
FDA advised that healthcare professionals should be aware of the risks of using codeine in children, particularly in those who have undergone tonsillectomy and/or adenoidectomy for obstructive sleep apnea syndrome. If prescribing codeine-containing drugs, the lowest effective dose for the shortest period of time should be used on an as-needed basis. And parents/caregivers who observe unusual sleepiness, confusion, or difficult or noisy breathing in their child should seek medical attention immediately, as these are signs of overdose.

Please refer to the following website in FDA for details: http://www.fda.gov/Safety/MedWatch/../ucm315627.htm

In Hong Kong, there are about 362 registered pharmaceutical products containing codeine and most of them are in syrup form. Codeine is an ingredient used to relieve pain and cough. No relevant adverse drug reaction report was received by Department of Health. In view of the FDA’s recommendation, a letter to inform healthcare professional will be issued.

Ends/ Thursday, August 16, 2012
Issued at HKT 15:00
 
Related Information:
Canada: Prescription cough and cold products containing opioids and the risk of ... Posted 2020-08-25
Canada: Non-prescription pain relief products containing codeine are not recomme... Posted 2020-08-01
Canada: Summary Safety Review - Opioid-containing cough and cold products - Asse... Posted 2019-02-19
中國:國家藥品監督管理局關於修訂含可待因感冒藥說明書的公告(2018年第63號)(Chinese Only) Posted 2018-09-07
FDA requires labeling changes for prescription opioid cough and cold medicines t... Posted 2018-01-12
The US:FDA Drug Safety Communication:FDA requires labeling changes for prescript... Posted 2018-01-12
Australia: Safety review: Codeine use in children and ultra-rapid metabolisers: ... Posted 2017-11-29
China: CFDA announcement on revision of package insert of medicines containing C... Posted 2017-01-05
Singapore: Restrictions on the use of codeine-containing products in children an... Posted 2016-12-21
Australia: Update on the proposal for the rescheduling of codeine products - Cod... Posted 2016-12-20
Canada: New safety measures for prescription codeine and hydrocodone to further ... Posted 2016-07-29
Singapore: Recommendations on the use of codeine-containing products for treatme... Posted 2016-07-05
Australia: Safety review: Codeine use in children and ultra-rapid metabolisers Posted 2015-10-02
The United States: Codeine cough-and-cold medicines in children: Drug Safety Com... Posted 2015-07-02
The United Kingdom: Drug safety update: Codeine for cough and cold: restricted u... Posted 2015-04-30
European Union: Codeine not to be used in children below 12 years for cough and ... Posted 2015-04-25
European Union : PRAC recommends restrictions on the use of codeine for cough an... Posted 2015-03-14
Singapore: Overseas recommendations on the use of codeine-containing products fo... Posted 2014-09-05
European Union: Start of review of codeine-containing medicines when used for co... Posted 2014-04-12
Updates on the use of codeine Posted 2013-06-29
European Union: PRAC recommends restricting the use of codeine when used for pai... Posted 2013-06-15
Canada: Health Canada’s review recommends codeine only be used in patients aged ... Posted 2013-06-07
Codeine - Recommends only be used in patients aged 12 and over (Letters to Healt... Posted 2013-06-07
The United States: FDA Drug Safety Communication: Safety review update of codein... Posted 2013-02-21
FDA: Codeine use in certain children after tonsillectomy and/or adenoidectomy ma... Posted 2012-08-16
 
back